Bitcoin breaks $81,000 for first time on Trump trades; UK government sells £1bn of NatWest shares – business live
Cryptocurrency more than doubles since January on hopes of lighter regulation; latest share sale takes UK Treasury’s holding in NatWest to 11.4%The British biotech sector has received a boost, after London-based Autolus Therapeutics, a UCL spinout, received US regulatory approval for its new treatment for a rare form of leukaemia.The US Food and Drug Administration has given the UK biotech marketing approval for Aucatzyl, for the treatment of adults with acute lymphoblastic leukaemia (ALL), a severe form of blood cancer that is fatal without treatment.Adult ALL is an extremely aggressive cancer, and there is a high unmet medical need that exists in the treatment of patients with this disease once they relapse, where historically they suffer from poor outcomes.This milestone approval, based on the demonstrated clinical benefit of Aucatzyl, brings new hope for adult patients with relapsed/refractory B-ALL.This milestone is the culmination of many years of hard work, the foundational work by our partners at UCL and the unwavering commitment of our internal team, our external partners and shareholders. Continue reading...
admin
Cryptocurrency more than doubles since January on hopes of lighter regulation; latest share sale takes UK Treasury’s holding in NatWest to 11.4%
The British biotech sector has received a boost, after London-based Autolus Therapeutics, a UCL spinout, received US regulatory approval for its new treatment for a rare form of leukaemia.
The US Food and Drug Administration has given the UK biotech marketing approval for Aucatzyl, for the treatment of adults with acute lymphoblastic leukaemia (ALL), a severe form of blood cancer that is fatal without treatment.
Adult ALL is an extremely aggressive cancer, and there is a high unmet medical need that exists in the treatment of patients with this disease once they relapse, where historically they suffer from poor outcomes.
This milestone approval, based on the demonstrated clinical benefit of Aucatzyl, brings new hope for adult patients with relapsed/refractory B-ALL.
This milestone is the culmination of many years of hard work, the foundational work by our partners at UCL and the unwavering commitment of our internal team, our external partners and shareholders.
Continue reading...
